Brelovitug Meets Primary Endpoint in Phase 3 AZURE-1 Hepatitis Delta Trial

3 Likes

Very encouraging news for the HDV community. As a patient living with chronic hepatitis D and currently seeking access to effective HDV treatment, I am especially hopeful to see these Phase 3 results. I sincerely hope this progress will bring new hope and real treatment opportunities to patients around the world, especially those who still have very limited options. I wish the entire Mirum team continued success, strength and good luck in all your future work. Thank you for your dedication and for working to bring new hope to people living with hepatitis D.

5 Likes